Myriad Genetics Inc (MYGN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $542.92M
Last updated: Nov 17, 2026 at 11:06 AM ET
Myriad Genetics Inc (MYGN) Earnings: Report Dates and Results
Myriad Genetics (MYGN) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Myriad Genetics reported EPS of -$0.21, above the -$0.25 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MYGN has an expected report date of Feb 22, 2027.
MYGN Earnings Call
The latest MYGN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, MYGN beat 26, missed 11 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $202.70M, down 1.5% from $205.70M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.21 | -$0.25 | -$0.27 - -$0.15 | +16.00% | Beat | N/A | 8 | 0 up, 8 down | Nov 4, 2026 | $202.70M |
| Jun 30, 2026 | -$0.33 | -$0.08 | -$0.12 - $0.03 | -312.50% | Miss | -760.0% | 9 | 1 up, 6 down | Jul 30, 2026 | $190.70M |
| Mar 31, 2026 | -$0.09 | -$0.07 | -$0.09 - -$0.01 | -28.57% | Miss | N/A | 10 | 1 up, 1 down | May 5, 2026 | $200.40M |
| Dec 31, 2025 | $0.04 | -$0.02 | -$0.02 - $0.00 | +332.56% | Beat | +33.3% | 12 | 0 up, 2 down | Feb 23, 2026 | $209.80M |
| Sep 30, 2025 | -$0.29 | -$0.01 | -$0.05 - $0.01 | N/A | N/A | -583.3% | 13 | 0 up, 0 down | Nov 3, 2025 | $205.70M |
| Jun 30, 2025 | $0.05 | -$0.01 | -$0.03 - $0.05 | +600.00% | Beat | 0.0% | 15 | 1 up, 0 down | Aug 5, 2025 | $213.10M |
| Mar 31, 2025 | -$0.03 | -$0.05 | -$0.08 - $0.01 | +40.00% | Beat | N/A | 16 | 2 up, 0 down | May 6, 2025 | $195.90M |
| Dec 31, 2024 | $0.03 | $0.03 | $0.02 - $0.05 | -0.99% | Miss | -25.0% | 16 | 2 up, 0 down | Feb 24, 2025 | $210.60M |
| Sep 30, 2024 | $0.06 | $0.02 | $0.00 - $0.05 | +200.00% | Beat | N/A | 15 | 2 up, 0 down | Nov 7, 2024 | $213.30M |
| Jun 30, 2024 | $0.05 | -$0.01 | -$0.05 - $0.01 | +600.00% | Beat | N/A | 13 | 1 up, 0 down | Aug 6, 2024 | $211.50M |
| Mar 31, 2024 | -$0.01 | -$0.11 | -$0.18 - -$0.03 | +90.91% | Beat | N/A | 12 | 0 up, 0 down | May 7, 2024 | $202.20M |
| Dec 31, 2023 | $0.04 | $0.01 | $0.00 - $0.02 | +300.00% | Beat | N/A | 11 | 0 up, 0 down | Feb 27, 2024 | $196.60M |
| Sep 30, 2023 | -$0.03 | -$0.08 | -$0.16 - -$0.02 | +62.50% | Beat | N/A | 9 | 0 up, 0 down | Nov 6, 2023 | $191.90M |
| Jun 30, 2023 | -$0.08 | -$0.09 | -$0.12 - $0.00 | +11.11% | Beat | -300.0% | 8 | 0 up, 1 down | Aug 3, 2023 | $183.50M |
| Mar 31, 2023 | -$0.21 | -$0.19 | -$0.21 - -$0.18 | -10.53% | Miss | N/A | 9 | 0 up, 0 down | May 3, 2023 | $181.20M |
| Dec 31, 2022 | -$0.12 | -$0.16 | -$0.25 - -$0.14 | +25.00% | Beat | N/A | 9 | 0 up, 0 down | Feb 28, 2023 | $177.80M |
| Sep 30, 2022 | -$0.19 | -$0.08 | -$0.22 - $0.02 | -137.50% | Miss | N/A | 9 | 0 up, 1 down | Nov 1, 2022 | $156.40M |
| Jun 30, 2022 | $0.04 | $0.02 | -$0.14 - $0.07 | +100.00% | Beat | -66.7% | 8 | 0 up, 0 down | Aug 4, 2022 | $179.30M |
| Mar 31, 2022 | -$0.03 | -$0.09 | -$0.13 - $0.00 | +66.67% | Beat | N/A | 7 | 0 up, 0 down | May 5, 2022 | $164.90M |
| Dec 31, 2021 | -$0.02 | -$0.02 | -$0.11 - $0.06 | 0.00% | In line | N/A | 9 | 0 up, 0 down | Feb 24, 2022 | $160.80M |
| Sep 30, 2021 | -$0.02 | -$0.01 | -$0.18 - $0.11 | -100.00% | Miss | N/A | 10 | 5 up, 0 down | Nov 2, 2021 | $167.30M |
| Jun 30, 2021 | $0.12 | -$0.10 | -$0.27 - $0.04 | +220.00% | Beat | N/A | 10 | N/A | Aug 3, 2021 | $189.40M |
| Mar 31, 2021 | -$0.06 | -$0.15 | -$0.32 - -$0.06 | +60.00% | Beat | N/A | 8 | N/A | May 3, 2021 | $173.10M |
| Dec 31, 2020 | -$0.12 | -$0.12 | -$0.15 - -$0.11 | 0.00% | In line | -152.2% | 3 | N/A | Feb 23, 2021 | $154.60M |
| Sep 30, 2020 | -$0.15 | -$0.30 | -$0.43 - -$0.19 | +50.00% | Beat | -287.5% | 8 | N/A | Nov 9, 2020 | $145.20M |
| Jun 30, 2020 | -$0.31 | -$0.47 | -$0.83 - -$0.15 | +34.04% | Beat | -175.6% | 9 | N/A | Aug 13, 2020 | $93.20M |
| Mar 31, 2020 | -$0.08 | $0.01 | -$0.03 - $0.07 | -900.00% | Miss | -117.4% | 9 | N/A | May 5, 2020 | $145.20M |
| Dec 31, 2019 | $0.23 | $0.29 | N/A | -20.69% | Miss | -39.5% | 7 | N/A | Feb 6, 2020 | $93.20M |
| Sep 30, 2019 | $0.08 | $0.31 | $0.31 - $0.38 | -74.19% | Miss | -81.4% | 9 | N/A | Nov 4, 2019 | $186.30M |
| Jun 30, 2019 | $0.41 | $0.48 | $0.41 - $0.50 | -14.58% | Miss | +7.9% | 11 | N/A | Aug 13, 2019 | $215.40M |
| Mar 31, 2019 | $0.46 | $0.43 | $0.35 - $0.45 | +6.98% | Beat | +48.4% | 12 | N/A | May 7, 2019 | $216.60M |
| Dec 31, 2018 | $0.38 | $0.39 | $0.36 - $0.48 | -2.56% | Miss | +22.6% | 11 | N/A | Feb 5, 2019 | $216.80M |
| Sep 30, 2018 | $0.43 | $0.31 | $0.29 - $0.34 | +38.71% | Beat | +65.4% | 8 | N/A | Nov 6, 2018 | $202.30M |
| Jun 30, 2018 | $0.38 | $0.33 | $0.31 - $0.35 | +15.15% | Beat | +26.7% | 13 | N/A | Aug 21, 2018 | $193.90M |
| Mar 31, 2018 | $0.31 | $0.27 | $0.26 - $0.28 | +14.81% | Beat | +14.8% | 13 | N/A | May 8, 2018 | $183.10M |
| Dec 31, 2017 | $0.31 | $0.24 | $0.22 - $0.27 | +29.17% | Beat | +19.2% | 13 | N/A | Feb 6, 2018 | $187.90M |
| Sep 30, 2017 | $0.26 | $0.21 | $0.19 - $0.23 | +23.81% | Beat | +13.0% | 13 | N/A | Nov 7, 2017 | $178.80M |
| Jun 30, 2017 | $0.30 | $0.26 | $0.14 - $0.28 | +15.38% | Beat | -6.3% | 13 | N/A | Aug 8, 2017 | $157.80M |
| Mar 31, 2017 | $0.27 | $0.24 | N/A | +12.50% | Beat | -34.1% | N/A | N/A | May 2, 2017 | $196.90M |
| Dec 31, 2016 | $0.26 | $0.24 | N/A | +8.33% | Beat | -42.2% | N/A | N/A | Feb 7, 2017 | $196.50M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.23, after $0.13 the year before. It was $1.22 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.23 | -276.9% |
| Dec 31, 2024 | $0.13 | N/A |
| Dec 31, 2023 | -$0.28 | N/A |
| Dec 31, 2022 | -$0.30 | -1600.0% |
| Dec 31, 2021 | $0.02 | N/A |
| Dec 31, 2020 | -$0.66 | -155.9% |
| Dec 31, 2019 | $1.18 | -21.3% |
| Dec 31, 2018 | $1.50 | +31.6% |
| Dec 31, 2017 | $1.14 | -6.6% |
| Dec 31, 2016 | $1.22 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,463 | 6 | |
| 2026Q1 | Mar 31, 2026 | 8,867 | 12 | |
| 2025Q4 | Dec 31, 2025 | 8,339 | 15 | |
| 2025Q3 | Sep 30, 2025 | 8,276 | 13 | |
| 2025Q2 | Jun 30, 2025 | 7,854 | 17 | |
| 2025Q1 | Mar 31, 2025 | 10,060 | 14 | |
| 2024Q4 | Dec 31, 2024 | 6,461 | 15 | |
| 2024Q3 | Sep 30, 2024 | 10,337 | 19 |
2026Q3 Earnings Call
Opening remarks
Matthew Scalo Senior Vice President of Investor Relations Good afternoon, and welcome to the Myriad Genetics Third Quarter 2026 Earnings Call. During the call, we will review financial results we released today, and afterwards, we will host a Q&A session. Our earnings release was issued this afternoon on Form 8-K and can be found on our website at investor.myriad.com. I'm Matt Scalo, Senior Vice President of Investor Relations. And on the call with me today are Sam Raha, our President and Chief Executive Officer; and Ben Wheeler, our Chief Financial Officer. Joining for Q&A will be Vishal Sikri, Executive Vice President of Commercial; and Mark Verratti, our Chief Operating Officer. This call can be heard live via webcast at investor.myriad.com, and a recording will be archived in the Investors section of our website, along with the slide presentation. Please note that some of the information presented today contains projections or other forward-looking statements regarding future events or the future financial performance of the company. These statements are based on management's current expectations, and the actual events or results may differ materially and adversely from these expectations for a variety of reasons. We refer you to the documents the company files from time to time with the SEC, specifically the company's annual report on Form 10-K, its quarterly reports on Form 10-Q and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in our projections or forward-looking statements. I'll now turn the call over to Sam.
Samraat Raha President and Chief Executive Officer Thanks, Matt. Good afternoon, everyone, and thank you for joining us. I want to start by welcoming Vishal Sikri to our earnings call. Vishal joined Myriad in 2025 as our SVP of Product and was recently promoted to Executive Vice President of Commercial, where he is now overseeing sales, marketing and product. Vishal has a deep understanding of molecular diagnostics and oncology as well as extensive business and commercial leadership experience. As Matt mentioned, Vishal is here in the room and available to participate in the Q&A portion of our call today, along with Mark Beratti. Before we discuss third quarter results, I want to start by framing the context for the last few months. We understand the key challenges that we've been facing: continued softness in our Prenatal Health business, reimbursement pressure on HCT and financial stability. We have been taking decisive actions to address the challenges, and I am pleased by the progress we're making on multiple fronts. To materially strengthen Myriad going forward, we've been advancing our work on a number of initiatives. First, we've done a rigorous review of our product portfolio to determine how to maximize shareholder value and sharpen Myriad's focus.
Frequently Asked Questions About MYGN
When is Myriad Genetics's next earnings date?
Myriad Genetics's next earnings report is expected for Feb 22, 2027.
Did MYGN beat earnings estimates last quarter?
Yes. Myriad Genetics reported EPS of -$0.21 for the quarter ended Sep 30, 2026, above the -$0.25 estimate, a 16.00% surprise.
What EPS do analysts expect from MYGN next quarter?
The consensus EPS estimate for Myriad Genetics for the quarter ending Dec 31, 2026 is -$0.24 from 11 analysts, with estimates from -$0.32 to -$0.17.
How often does MYGN beat earnings estimates?
Myriad Genetics beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +105.81%.
MYGN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts